221 related articles for article (PubMed ID: 16242637)
1. Locomotor activity and evoked dopamine release are reduced in mice overexpressing A30P-mutated human alpha-synuclein.
Yavich L; Oksman M; Tanila H; Kerokoski P; Hiltunen M; van Groen T; Puoliväli J; Männistö PT; García-Horsman A; MacDonald E; Beyreuther K; Hartmann T; Jäkälä P
Neurobiol Dis; 2005 Nov; 20(2):303-13. PubMed ID: 16242637
[TBL] [Abstract][Full Text] [Related]
2. Behavioral and neurochemical effects of wild-type and mutated human alpha-synuclein in transgenic mice.
Richfield EK; Thiruchelvam MJ; Cory-Slechta DA; Wuertzer C; Gainetdinov RR; Caron MG; Di Monte DA; Federoff HJ
Exp Neurol; 2002 May; 175(1):35-48. PubMed ID: 12009758
[TBL] [Abstract][Full Text] [Related]
3. Chronic exposure to manganese decreases striatal dopamine turnover in human alpha-synuclein transgenic mice.
Peneder TM; Scholze P; Berger ML; Reither H; Heinze G; Bertl J; Bauer J; Richfield EK; Hornykiewicz O; Pifl C
Neuroscience; 2011 Apr; 180():280-92. PubMed ID: 21333719
[TBL] [Abstract][Full Text] [Related]
4. Locomotor hyperactivity and alterations in dopamine neurotransmission are associated with overexpression of A53T mutant human alpha-synuclein in mice.
Unger EL; Eve DJ; Perez XA; Reichenbach DK; Xu Y; Lee MK; Andrews AM
Neurobiol Dis; 2006 Feb; 21(2):431-43. PubMed ID: 16230020
[TBL] [Abstract][Full Text] [Related]
5. Behavioural and neurochemical response of alpha-synuclein A30P transgenic mice to the effects of L-DOPA.
Oksman M; Tanila H; Yavich L
Neuropharmacology; 2009 Mar; 56(3):647-52. PubMed ID: 19084027
[TBL] [Abstract][Full Text] [Related]
6. Motor impairment and aberrant production of neurochemicals in human alpha-synuclein A30P+A53T transgenic mice with alpha-synuclein pathology.
Ikeda M; Kawarabayashi T; Harigaya Y; Sasaki A; Yamada S; Matsubara E; Murakami T; Tanaka Y; Kurata T; Wuhua X; Ueda K; Kuribara H; Ikarashi Y; Nakazato Y; Okamoto K; Abe K; Shoji M
Brain Res; 2009 Jan; 1250():232-41. PubMed ID: 18992718
[TBL] [Abstract][Full Text] [Related]
7. Lack of nigral pathology in transgenic mice expressing human alpha-synuclein driven by the tyrosine hydroxylase promoter.
Matsuoka Y; Vila M; Lincoln S; McCormack A; Picciano M; LaFrancois J; Yu X; Dickson D; Langston WJ; McGowan E; Farrer M; Hardy J; Duff K; Przedborski S; Di Monte DA
Neurobiol Dis; 2001 Jun; 8(3):535-9. PubMed ID: 11442360
[TBL] [Abstract][Full Text] [Related]
8. Changes in adult olfactory bulb neurogenesis in mice expressing the A30P mutant form of alpha-synuclein.
Marxreiter F; Nuber S; Kandasamy M; Klucken J; Aigner R; Burgmayer R; Couillard-Despres S; Riess O; Winkler J; Winner B
Eur J Neurosci; 2009 Mar; 29(5):879-90. PubMed ID: 19291219
[TBL] [Abstract][Full Text] [Related]
9. Abnormal compartmentalization of norepinephrine in mouse dentate gyrus in alpha-synuclein knockout and A30P transgenic mice.
Yavich L; Jäkälä P; Tanila H
J Neurochem; 2006 Nov; 99(3):724-32. PubMed ID: 16824047
[TBL] [Abstract][Full Text] [Related]
10. Comparison of motor performance, brain biochemistry and histology of two A30P α-synuclein transgenic mouse strains.
Piltonen M; Savolainen M; Patrikainen S; Baekelandt V; Myöhänen TT; Männistö PT
Neuroscience; 2013 Feb; 231():157-68. PubMed ID: 23219665
[TBL] [Abstract][Full Text] [Related]
11. A chemical chaperone, sodium 4-phenylbutyric acid, attenuates the pathogenic potency in human alpha-synuclein A30P + A53T transgenic mice.
Ono K; Ikemoto M; Kawarabayashi T; Ikeda M; Nishinakagawa T; Hosokawa M; Shoji M; Takahashi M; Nakashima M
Parkinsonism Relat Disord; 2009 Nov; 15(9):649-54. PubMed ID: 19345133
[TBL] [Abstract][Full Text] [Related]
12. Alpha-synuclein A30P point-mutation generates age-dependent nigrostriatal deficiency in mice.
Plaas M; Karis A; Innos J; Rebane E; Baekelandt V; Vaarmann A; Luuk H; Vasar E; Koks S
J Physiol Pharmacol; 2008 Jun; 59(2):205-16. PubMed ID: 18622040
[TBL] [Abstract][Full Text] [Related]
13. Olfactory neuron-specific expression of A30P α-synuclein exacerbates dopamine deficiency and hyperactivity in a novel conditional model of early Parkinson's disease stages.
Nuber S; Petrasch-Parwez E; Arias-Carrión O; Koch L; Kohl Z; Schneider J; Calaminus C; Dermietzel R; Samarina A; Boy J; Nguyen HP; Teismann P; Velavan TP; Kahle PJ; von Hörsten S; Fendt M; Krüger R; Riess O
Neurobiol Dis; 2011 Nov; 44(2):192-204. PubMed ID: 21767644
[TBL] [Abstract][Full Text] [Related]
14. Mitochondrial associated metabolic proteins are selectively oxidized in A30P alpha-synuclein transgenic mice--a model of familial Parkinson's disease.
Poon HF; Frasier M; Shreve N; Calabrese V; Wolozin B; Butterfield DA
Neurobiol Dis; 2005 Apr; 18(3):492-8. PubMed ID: 15755676
[TBL] [Abstract][Full Text] [Related]
15. Trypsin disrupts the trafficking of the human dopamine transporter by alpha-synuclein and its A30P mutant.
Wersinger C; Vernier P; Sidhu A
Biochemistry; 2004 Feb; 43(5):1242-53. PubMed ID: 14756560
[TBL] [Abstract][Full Text] [Related]
16. Selective loss of nigral dopamine neurons induced by overexpression of truncated human alpha-synuclein in mice.
Wakamatsu M; Ishii A; Iwata S; Sakagami J; Ukai Y; Ono M; Kanbe D; Muramatsu S; Kobayashi K; Iwatsubo T; Yoshimoto M
Neurobiol Aging; 2008 Apr; 29(4):574-85. PubMed ID: 17174013
[TBL] [Abstract][Full Text] [Related]
17. AAV1/2-induced overexpression of A53T-α-synuclein in the substantia nigra results in degeneration of the nigrostriatal system with Lewy-like pathology and motor impairment: a new mouse model for Parkinson's disease.
Ip CW; Klaus LC; Karikari AA; Visanji NP; Brotchie JM; Lang AE; Volkmann J; Koprich JB
Acta Neuropathol Commun; 2017 Feb; 5(1):11. PubMed ID: 28143577
[TBL] [Abstract][Full Text] [Related]
18. Role of alpha-synuclein in synaptic glutamate release.
Gureviciene I; Gurevicius K; Tanila H
Neurobiol Dis; 2007 Oct; 28(1):83-9. PubMed ID: 17689254
[TBL] [Abstract][Full Text] [Related]
19. Nigrostriatal overabundance of α-synuclein leads to decreased vesicle density and deficits in dopamine release that correlate with reduced motor activity.
Gaugler MN; Genc O; Bobela W; Mohanna S; Ardah MT; El-Agnaf OM; Cantoni M; Bensadoun JC; Schneggenburger R; Knott GW; Aebischer P; Schneider BL
Acta Neuropathol; 2012 May; 123(5):653-69. PubMed ID: 22361813
[TBL] [Abstract][Full Text] [Related]
20. Dopamine transporter-mediated cytotoxicity of 6-hydroxydopamine in vitro depends on expression of mutant alpha-synucleins related to Parkinson's disease.
Lehmensiek V; Tan EM; Liebau S; Lenk T; Zettlmeisl H; Schwarz J; Storch A
Neurochem Int; 2006 Apr; 48(5):329-40. PubMed ID: 16406146
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
